Surfactant protein-D is more useful than Krebs von den Lungen 6 as a marker for the early diagnosis of interstitial pneumonitis during pegylated interferon treatment for chronic hepatitis C

Hepato-Gastroenterology

Volumn 59, Issue 119, 2012, Pages 2260-2263

  Ishikawa, Toru ^a   Kubota, Tomoyuki ^a   Abe, Hiroyuki ^a   Hirose, Kanae ^a   Nagashima, Aiko ^a   Togashi, Tadayuki ^a   Seki, Keiichi ^a   Honma, Terasu ^a   Yoshida, Toshiaki ^a   Kamimura, Tomoteru ^a  

^a Saiseikai Niigata Daini Hospital   (Japan)

Author keywords

Interstitial pneumonitis; Krebs von den Lungen 6; Pegylated interferon; Surfactant protein D

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; KREBS VON DEN LUNGEN 6; MEMBRANE PROTEIN; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; STEROID; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL PNEUMONIA; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DYSPNEA; EARLY DIAGNOSIS; EMPHYSEMA; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; IMAGE ANALYSIS; INTERSTITIAL PNEUMONIA; LIVER BIOPSY; LUNG EXAMINATION; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STEROID THERAPY; THORAX RADIOGRAPHY; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; EARLY DIAGNOSIS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MUCIN-1; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; RECOMBINANT PROTEINS; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872064879     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge10868     Document Type: Article

References (17)

1. Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358:958-965.
2. Naranjo CA, Busto U, Sellers EM, et al.: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239-245.
3. Kumar KS, Russo MW, Borczuk AC, et al.: Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol 2002; 97:2432-2440.
4. Bini EJ, Weinshel EH: Severe exacerbation of asthma: a new side effect of interferon-alpha in patients with asthma and chronic hepatitis C. Mayo Clin Proc 1999; 74:367-370.
5. Kohno N, Akiyama M, Kyoizumi S, Hakoda M, Kobuke K, Yamakido M: Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 1988; 18:203-216.
6. Honda Y, Kuroki Y, Matsuura E, et al.: Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 1995; 152:1860-1866.
7. Fried MW, Hoofnagle JH: Therapy of hepatitis C. Seminar Liver Dis 1995; 15:82-91.
8. Okanoue T, Sakamoto S, Itoh Y, et al.: Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25:283-291.
9. Ishizaki T, Sasaki F, Ameshima S, et al.: Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis. Eur Respir J 1996; 9:2691-2696.
10. Chin K, Tabata C, Sataka N, Nagai S, Moriyasu F, Kuno K: Pneumonitis associated with natural and recombinant interferon α therapy for chronic hepatitis C. Chest 1994; 105:939-941.
11. Yokoyama A, Kondo K, Nakajima M, et al.: Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 2006; 11:164-168.
12. Kuroki Y, Takahashi H, Chiba H, Akino T: Surfactant proteins A and D: disease markers. Biochim Biophys Acta 1998; 1408:334-345.
13. Takahashi H, Fujishima T, Koba H, et al.: Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med 2000; 162:1109-1114.
14. Honda Y, Kuroki Y, Matsuura E, et al.: Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 1995; 152:1860-1866.
15. Takahashi H, Chiba H, Shiratori M, Tachibana T, Abe S: Elevated serum surfactant protein A and D in pulmonary alveolar microlithiasis. Respirology 2006; 11:330-333.
16. Yanaba K, Hasegawa M, Takehara K, Sato S: Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol 2004; 31:1112-1120.
17. Takahashi H, Fujishima T, Koba H, et al.: Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med 2000; 162:1109-1114.